Smoking is an infamously dangerous and hard-to-kick habit, and one that is the leading cause of preventable, premature death globally. Tobacco will claim the lives of up to two-thirds of all long-term tobacco users. If you’re out of luck with gums or patches, a new clinical trial has some potentially exciting news.
Data published in the March 2026 issue of the Journal of the American Medical Association indicates that psilocybin therapy has more than “6 times greater odds” of helping you abstain from smoking than nicotine patches.
Here’s exactly what the study authors did, the mechanisms at play, and what this might mean for those seeking an alternative treatment to conditions like addiction.
Published on March 10th, 2026, the trial in question, titled ‘Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial’, by Johnson & colleagues, makes a compelling claim.
“Psilocybin should be investigated further [as a treatment for] tobacco and other substance use disorders,” say the authors, based on their findings. Before we dive into their work, we must acknowledge the context behind their words.
Psychedelics like psilocybin have been ostracized from the scientific community for decades. Large evidentiary gaps in what we know about psychedelic-assisted therapy (PAT) have developed due to suppression and superstition that, in the 2020s, are finally starting to dissipate.
Researchers are finally lending credence to what psychedelic enthusiasts have known for decades: Compounds like psilocybin have significant potential utility as an alternative aid for various mental health ailments. To that end, Johnson et al. put psilocybin in the ring against nicotine patches - an intervention that, for most people, only works temporarily.
Here’s what they did.
Assigned randomly, participants received one dose of 30mg psilocybin or up to 10 weeks of nicotine patch treatment.
Objective: “Compare prolonged smoking abstinence rates” for single-dose psilocybin versus the patch, measured via a 6-month follow-up.
Worth noting: Participants also received cognitive-behavioral therapy (CBT) for both interventions.
Broadly, Johnson & colleagues remarked that psilocybin had significantly greater odds of smoking abstinence after six months: “Most smoking interventions result in modest long-term success,” they said.
“The psilocybin group had more than 6 times greater odds of prolonged abstinence” at a 6-month follow-up. The psilocybin group also smoked half as often each day before abstinence.
The mechanism: The authors believe that psilocybin’s “lack of direct interaction” with brain receptors targeted by traditional smoking interventions is responsible for the benefits seen here.
“[Psilocybin therapy] does not directly alter drug reinforcement…but may act via higher-order psychological systems, such as changes in self-concept and enhanced psychological flexibility.”
What they’re referring to is called neuroplasticity - the brain’s ability to loosen its cognitive holds and carve out new neural connections. This state allows disparate brain regions that don’t usually communicate to establish fresh links, powering the “mind expansion” people feel from psychedelics.
This study of over 80 individuals presents some reliable, well-constructed data about the potency of psilocybin in managing addiction. However, it is not without some drawbacks.
It’s also worth acknowledging the practical gap between the interventions. The psilocybin group spent more than double the amount of time in research settings as the nicotine patch users and so received more contact time with facilitators (which may have influenced outcomes) - mostly, the authors admit, because PAT takes 6-8 hours. Nicotine patches can be applied and forgotten about.
That convenience and lack of disruption to daily life are huge selling points for anti-smoking tools like the patch. For the time being, psilocybin can’t measure up logistically; it requires you to set aside an entire day in order to follow best practices for set, setting, and integration. But if the evidentiary support continues to grow, the benefits more than offset any practical hurdles.
Johnson et al.’s work is compelling, but it represents only a single data point in a larger ecosystem. Most of the existing literature on psilocybin’s medical utility has focused on mental health disorders like major depression or PTSD.
Still, the clinical lens is turning toward psilocybin’s value in managing addiction as well. In 2023, a systematic review and meta-analysis - that’s essentially a study of existing studies, from which the authors draw broader conclusions - acknowledged a “beneficial effect,” but stressed that more research is needed.